Elicio Therapeutics Prices $15M Direct Offering to Fund Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 50 minutes ago
0mins
Source: seekingalpha
- Offering Size: Elicio Therapeutics priced approximately 4.38 million shares at about $3.43 each, raising $15 million to fund the clinical development of ELI-002 7P, particularly targeting metastatic pancreatic ductal adenocarcinoma (PDAC).
- Investor Composition: The offering is led by two new fundamental institutional investors with participation from an existing large shareholder, indicating some market confidence in Elicio despite recent clinical data setbacks.
- Use of Proceeds: The net proceeds will support the Phase 1 clinical development of ELI-002 7P, advance the broader pipeline, and provide working capital and general corporate purposes, aiming to enhance the company's financial flexibility.
- Market Reaction: Following the offering announcement, Elicio's stock price dropped about 5% during pre-market trading on Thursday, reflecting investor concerns regarding the company's future prospects, particularly after disappointing Phase 2 data for its pancreatic cancer asset.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELTX
Wall Street analysts forecast ELTX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.910
Low
13.00
Averages
15.50
High
18.00
Current: 3.910
Low
13.00
Averages
15.50
High
18.00
About ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elicio Therapeutics Secures $15 Million in Direct Offering
- Financing Agreement: Elicio Therapeutics has entered into a definitive agreement with two new institutional investors and a large existing shareholder to issue 4,380,313 shares of common stock in a registered direct offering, expected to raise approximately $15 million, thereby strengthening the company's financial position to support clinical development.
- Use of Proceeds: The net proceeds from this offering will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, while also supporting the company's pipeline and general corporate purposes, ensuring the continuity and stability of its R&D activities.
- Market Potential Assessment: ELI-002 7P targets the most common KRAS mutations present in 25% of solid tumors, aiming to enhance immune responses and potentially provide new treatment options for high-risk patients, thereby expanding market share.
- Strategic Development Direction: Elicio plans to initiate a Phase 1 study in metastatic pancreatic cancer following funding, designed to rapidly assess clinical activity and inform future treatment strategies, demonstrating the company's ongoing innovation in personalized cancer immunotherapy.
See More
Elicio Therapeutics Prices $15M Direct Offering to Fund Clinical Development
- Offering Size: Elicio Therapeutics priced approximately 4.38 million shares at about $3.43 each, raising $15 million to fund the clinical development of ELI-002 7P, particularly targeting metastatic pancreatic ductal adenocarcinoma (PDAC).
- Investor Composition: The offering is led by two new fundamental institutional investors with participation from an existing large shareholder, indicating some market confidence in Elicio despite recent clinical data setbacks.
- Use of Proceeds: The net proceeds will support the Phase 1 clinical development of ELI-002 7P, advance the broader pipeline, and provide working capital and general corporate purposes, aiming to enhance the company's financial flexibility.
- Market Reaction: Following the offering announcement, Elicio's stock price dropped about 5% during pre-market trading on Thursday, reflecting investor concerns regarding the company's future prospects, particularly after disappointing Phase 2 data for its pancreatic cancer asset.
See More
Biotech Companies See Significant Stock Gains
- Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
- SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
- Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
- Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
See More
Elicio Therapeutics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Elicio Therapeutics has engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, indicating significant legal risks that could impact the company's market reputation and shareholder confidence.
- Disappointing Clinical Trial Results: On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P study did not meet the pre-specified primary endpoint of disease-free survival (DFS), suggesting setbacks in its pancreatic cancer treatment development, which may hinder future funding and partnership opportunities.
- Significant Stock Price Drop: Following the negative news, Elicio's stock price plummeted by $9.97, or 70.96%, closing at $4.08 per share, reflecting market pessimism regarding the company's outlook and potentially leading to further declines in investor confidence.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, may initiate class action lawsuits against Elicio, and if fraud is confirmed, the company could face substantial damages, exacerbating its financial pressures.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
Elicio Therapeutics Secures $15 Million in Direct Offering
- Financing Agreement: Elicio Therapeutics has entered into a definitive agreement with two new institutional investors and a large existing shareholder to issue 4,380,313 shares of common stock in a registered direct offering, expected to raise approximately $15 million, thereby strengthening the company's financial position to support clinical development.
- Use of Proceeds: The net proceeds from this offering will primarily fund the Phase 1 clinical development of ELI-002 7P for metastatic pancreatic cancer, while also supporting the company's pipeline and general corporate purposes, ensuring the continuity and stability of its R&D activities.
- Market Potential Assessment: ELI-002 7P targets the most common KRAS mutations present in 25% of solid tumors, aiming to enhance immune responses and potentially provide new treatment options for high-risk patients, thereby expanding market share.
- Strategic Development Direction: Elicio plans to initiate a Phase 1 study in metastatic pancreatic cancer following funding, designed to rapidly assess clinical activity and inform future treatment strategies, demonstrating the company's ongoing innovation in personalized cancer immunotherapy.
See More
Elicio Therapeutics Prices $15M Direct Offering to Fund Clinical Development
- Offering Size: Elicio Therapeutics priced approximately 4.38 million shares at about $3.43 each, raising $15 million to fund the clinical development of ELI-002 7P, particularly targeting metastatic pancreatic ductal adenocarcinoma (PDAC).
- Investor Composition: The offering is led by two new fundamental institutional investors with participation from an existing large shareholder, indicating some market confidence in Elicio despite recent clinical data setbacks.
- Use of Proceeds: The net proceeds will support the Phase 1 clinical development of ELI-002 7P, advance the broader pipeline, and provide working capital and general corporate purposes, aiming to enhance the company's financial flexibility.
- Market Reaction: Following the offering announcement, Elicio's stock price dropped about 5% during pre-market trading on Thursday, reflecting investor concerns regarding the company's future prospects, particularly after disappointing Phase 2 data for its pancreatic cancer asset.
See More
Biotech Companies See Significant Stock Gains
- Can-Fite Surge: Can-Fite BioPharma Ltd. (CANF) saw its stock soar over 55% to $4.63 following an update on its pancreatic cancer study, where the Phase 2a trial of Namodenoson met primary safety endpoints and showed durable survival outcomes, indicating strong future market potential as the company plans to advance to a Phase 2b combination study with chemotherapy.
- SeaStar Revenue Growth: SeaStar Medical Holding Corp. (ICU) experienced a stock increase of over 30% to $4.86, driven by no specific news, yet its flagship product QUELIMMUNE received FDA approval in 2024, with projected net product revenue of approximately $2 million in 2026, up from $1.2 million in 2025, reflecting strong market demand in critical care treatments.
- Elicio Strategic Refinement: Elicio Therapeutics Inc. (ELTX) jumped over 31% to $5.14, as it was added to the Russell 2000 and 3000 Indexes in 2026, despite its EL-002 product not meeting the primary endpoint in the AMPLIFY-7P trial, the company has refined its Phase 3 development strategy based on trial insights and plans to initiate a Phase 3 trial pending financing, showcasing ongoing R&D progress.
- Regentis European Rollout: Regentis Biomaterials Ltd. (RGNT) rose over 29% to $4.57, with no specific news, but its GelrinC product received CE Mark approval, and the company plans to begin European surgeon training this quarter as part of its commercial rollout preparations, indicating significant market expansion potential in regenerative medicine.
See More
Elicio Therapeutics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Elicio Therapeutics has engaged in securities fraud or other unlawful business practices, advising investors to contact them for more information, indicating significant legal risks that could impact the company's market reputation and shareholder confidence.
- Disappointing Clinical Trial Results: On June 15, 2026, Elicio announced that its Phase 2 AMPLIFY-7P study did not meet the pre-specified primary endpoint of disease-free survival (DFS), suggesting setbacks in its pancreatic cancer treatment development, which may hinder future funding and partnership opportunities.
- Significant Stock Price Drop: Following the negative news, Elicio's stock price plummeted by $9.97, or 70.96%, closing at $4.08 per share, reflecting market pessimism regarding the company's outlook and potentially leading to further declines in investor confidence.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities class action firm, may initiate class action lawsuits against Elicio, and if fraud is confirmed, the company could face substantial damages, exacerbating its financial pressures.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: Aditxt, Inc. (ADTX) surged 225% to $0.014 in pre-market trading, indicating strong market confidence in its growth potential, which may attract more investor interest.
- Other Gaining Stocks: Park Ha Biological Technology Co., Ltd. (BYAH) rose 40% to $1.68, while Spero Therapeutics, Inc. (SPRO) increased by 10% to $4.37, reflecting an overall positive sentiment in the biotech sector that could drive industry investment momentum.
- Pre-Market Losers: Elicio Therapeutics, Inc. (ELTX) fell 20% to $3.78, and Profusa, Inc. (PFSA) dropped 26% to $0.19, highlighting market concerns over certain companies, which may lead investors to reassess risks.
- Market Volatility Factors: The fluctuations in pre-market trading are primarily driven by U.S. patent protections, FDA approvals, manufacturing deals, and trial goal misses, showcasing the complexities and potential risks within the biotech industry.
See More
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
- FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
- Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
- Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
- Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
See More
